jeremiah@devisedesigns.com, Author at Corcept Therapeutics

About jeremiah@devisedesigns.com

This author has not written his bio yet.
But we are proud to say that jeremiah@devisedesigns.com contributed 143 entries already.

Entries by jeremiah@devisedesigns.com

Relacorilant Improved Blood Pressure and Maintained Other Cardiometabolic Improvements in Long-term Study in Patients With Endogenous Hypercortisolism (Cushing Syndrome)

Dr. Richard J. Auchus • 2024 • WCIRDC

December 13, 2024

Open-label Extension Study Evaluating the Safety and Efficacy of Long-term Use of Relacorilant in Patients With Endogenous Hypercortisolism (Cushing Syndrome): Interim Analysis Results

Araque et al. • 2024 • WCIRDC

December 12, 2024

Medical Treatment of Hypercortisolism with Relacorilant: Final Results of the Phase 3 GRACE Study

Araque et al. • 2024 • WCIRDC

December 12, 2024

Prevalence of hypercortisolism in patients with difficult-to-control type 2 diabetes and cardiovascular disease: Results from CATALYST

Fonseca et al. • 2024 • WCIRDC

December 12, 2024

Prevalence of hypercortisolism in patients with difficult-to-control type 2 diabetes and high blood pressure: Results from CATALYST

Handelsman et al. • 2024 • WCIRDC

December 12, 2024

Open-label Extension Study Evaluating the Safety and Efficacy of Long-term Use of Relacorilant in Patients With Endogenous Hypercortisolism (Cushing Syndrome): Results from the First Interim Analysis

Badiu et al. • 2024 • AACE MENA 2024 Congress

November 25, 2024

Relacorilant Maintained Hypertension Improvement in Long-term Follow-up of Patients With Endogenous Hypercortisolism (Cushing Syndrome)

Gilis-Januszewska et al. • 2024 • AACE MENA 2024 Congress

November 25, 2024

Metabolomic and Lipidomic Analysis of Patients with Presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treated with the Selective Glucocorticoid Receptor Modulator Miricorilant

Kowdley et al. • 2024 • AASLD 2024 Congress

November 18, 2024

A Phase 1, Open-Label, Drug-Drug Interaction Study Designed to Evaluate the Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-gp Substrate Dabigatran Etexilate in Healthy Subjects

Kunta et al. • 2024 • AAPS 2024 Congress

October 31, 2024

Pharmacokinetics of the Selective Glucocorticoid Receptor Modulator Miricorilant in Healthy Volunteers and Patients with Presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Custodio et al. • 2024 • EASL 2024 Congress

June 10, 2024

© 2024 Corcept Therapeutics, Incorporated

Privacy Notice | Terms of Use | Site Map | Your Privacy Choices | LinkedIn | Youtube

Your Privacy Choices